Consistent with these previous results, in the present study, in the HG group, the fragmentation of EC organoids after treatment with XCT790 in combination with carboplatin was comparable to that after treatment with metformin combined with carboplatin, indicating that the addition of the ERRα inhibitor XCT790 could be considered for the method of patients with metabolic syndrome accompanied by EC. This evidence concerns the gene ESRRA and metabolic syndrome.